Australia’s healthcare informatics firm Pro Medicus (ASX:PME) is witnessing a rise of 0.9% to a record high of A$80.71, following a 12% surge earlier the week, consequent to a A$140 million ($90 million) contract win.

Key players like Morningstar, Jefferies and Bell Potter have increased their price targets on the company’s largest-ever contract.

Morningstar has upped its price target to A$33.50 and has forecasted a mid-cycle 71% EBIT margin by FY33.

Jefferies has escalated its price target to A$82 from A$71, attributing its decision to anticipated growth in the cardiology business which is expected to increase revenue by 2%-6% in the coming years.

Bell Potter has also elevated its price target to A$75 from A$70, expressing confident expectations that FY24 earnings are unlikely to disappoint.

According to London Stock Exchange group data, the median price target of the 12 analysts covering Pro Medicus (ASX:PME) currently stands at A$75.

Lastly, PME was last up 0.4% at A$80.30, bringing year-to-date gains to 45.3%.

Pro Medicus (ASX:PME) is a leading healthcare informatics firm providing radiology and imaging solutions.